Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail?

被引：42

作者：

Nguyen, T. N. ^{[1
,2
,3
,4
]}

Cumming, R. G. ^{[4
]}

Hilmer, S. N. ^{[1
,2
,3
]}

机构：

[1] Univ Sydney, Royal N Shore Hosp, Dept Clin Pharmacol, Sydney, NSW 2006, Australia

[2] Univ Sydney, Royal N Shore Hosp, Dept Aged Care, Sydney, NSW 2006, Australia

[3] Univ Sydney, Sydney Med Sch, Kolling Inst Med Res, Sydney, NSW 2006, Australia

[4] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2016年 / 46卷 / 01期

关键词：

atrial fibrillation; frailty; anticoagulant; anti-arrhythmic; stroke; bleeding; ANTICOAGULATION THERAPY; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; MAJOR HEMORRHAGE; HEART-FAILURE; HIGH-RISK; WARFARIN; STROKE; DIGOXIN; IMPACT;

D O I：

10.1111/imj.12912

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundFrailty is common in patients with atrial fibrillation and may impact on antithrombotic and anti-arrhythmic treatment. AimTo describe differences in clinical characteristics, prescription of antithrombotic and anti-arrhythmic medications and incidence of haemorrhage and stroke, between frail and non-frail older inpatients. MethodsProspective observational study in patients aged 65years with atrial fibrillation admitted to a teaching hospital in Sydney, Australia. Frailty was assessed using the Reported Edmonton Frail Scale, stroke risk with CHA2DS2-VASc score and bleeding risk with HAS-BLED score. Participants were followed after 6months for haemorrhages and strokes. ResultsWe recruited 302 patients (mean age 84.7 7.1years, 53.3% frail, 50% female, mean CHA2DS2-VASc 4.61 +/- 1.44, mean HAS-BLED 2.97 +/- 1.04). Frail participants were older and had more co-morbidities and higher risk of stroke but not haemorrhage. Upon discharge, 55.7% participants were prescribed with anticoagulants (49.3% frail, 62.6% non-frail, P = 0.02). Thirty-three per cent received antiplatelets only and 11.1% no antithrombotics, with no difference by frailty status. For anti-arrhythmics, 52.6% received rate-control drugs only, 11.8% rhythm-control drugs only and 13.5% both and 22.1% were not prescribed either, with no difference by frailty status. On univariate logistic regression, frailty decreased the likelihood of anticoagulant prescription (odds ratio (OR) 0.58, 95%CI 0.36-0.93), but this was not significant on multivariate analysis (OR 0.66, 95%CI 0.40-1.11). After 6months, overall incidence of ischaemic stroke was 2.1%, and in patients taking anticoagulants, incidence of major/severe bleeding was 6.3%, with no significant difference between frailty groups. ConclusionsFrailty status had little impact on antithrombotic prescription and no impact on anti-arrhythmic prescription.

引用

页码：86 / 95

页数：10

共 60 条

[41] Inflammation, Coagulation, and the Pathway to Frailty [J].

Kanapuru, Bindu ;

Ershler, William B. .

AMERICAN JOURNAL OF MEDICINE, 2009, 122 (07) :605-613

[42] Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial [J].

Mant, Jonathan ;

Hobbs, F. D. Richard ;

Fletcher, Kate ;

Roalfe, Andrea ;

Fitzmaurice, David ;

Lip, Gregory Y. H. ;

Murray, Ellen .

LANCET, 2007, 370 (9586) :493-503

[43] STROKE PREVENTION IN ATRIAL-FIBRILLATION STUDY - FINAL RESULTS [J].

MCBRIDE, R .

CIRCULATION, 1991, 84 (02) :527-539

[44] Underutilization of warfarin in older persons with chronic nonvalvular atrial fibrillation at high risk for developing stroke [J].

Mendelson, G ;

Aronow, WS .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1998, 46 (11) :1423-1424

[45]

Misiaszek B, 2005, CAN J CARDIOL, V21, P281

[46] Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty [J].

Mitchell, S. J. ;

Hilmer, S. N. ;

Murnion, B. P. ;

Matthews, S. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) :327-335

[47] From sarcopenia to frailty: a road less traveled [J].

Morley, John E. ;

von Haehling, Stephan ;

Anker, Stefan D. ;

Vellas, Bruno .

JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2014, 5 (01) :5-8

[48] Frailty Consensus: A Call to Action [J].

Morley, John E. ;

Vellas, Bruno ;

van Kan, G. Abellan ;

Anker, Stefan D. ;

Bauer, Juergen M. ;

Bernabei, Roberto ;

Cesari, Matteo ;

Chumlea, W. C. ;

Doehner, Wolfram ;

Evans, Jonathan ;

Fried, Linda P. ;

Guralnik, Jack M. ;

Katz, Paul R. ;

Malmstrom, Theodore K. ;

McCarter, Roger J. ;

Gutierrez Robledo, Luis M. ;

Rockwood, Ken ;

von Haehling, Stephan ;

Vandewoude, Maurits F. ;

Walston, Jeremy .

JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2013, 14 (06) :392-397

[49] Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study [J].

Mulder, Bart A. ;

Van Veldhuisen, Dirk J. ;

Crijns, Harry J. G. M. ;

Tijssen, Jan G. P. ;

Hillege, Hans L. ;

Alings, Marco ;

Rienstra, Michiel ;

Van den Berg, Maarten P. ;

Van Gelder, Isabelle C. .

HEART RHYTHM, 2014, 11 (09) :1543-1550

[50] The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation [J].

Perera, Vidya ;

Bajorek, Beata V. ;

Matthews, Slade ;

Hilmer, Sarah N. .

AGE AND AGEING, 2009, 38 (02) :156-162

← 1 2 3 4 5 6 →